Related Experiment Video

Updated: Jun 9, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

2-Methoxyestradiol: new perspectives in colon carcinoma treatment

Michele Parks1, Micol Tillhon, Francesca Donà

  • 1Istituto di Genetica Molecolare CNR, Via Abbiategrasso 207, I-27100 Pavia, Italy.

Molecular and Cellular Endocrinology
|September 7, 2010
PubMed

Insights

2-methoxyestradiol (2-ME) shows promise against colon carcinoma. This compound effectively inhibits cancer cell growth, induces cell cycle arrest, and triggers apoptosis and autophagy in colon cancer cell lines.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Colon carcinoma is a significant oncological challenge due to poor response to conventional chemotherapy.
  • Novel therapeutic strategies are urgently needed to overcome chemotherapy resistance in colon cancer.
  • 2-methoxyestradiol (2-ME), a metabolite of 17β-estradiol, exhibits anti-cancer properties but its efficacy in colon carcinoma is not well-established.

Purpose of the Study:

  • To investigate the anti-proliferative effects of 2-methoxyestradiol (2-ME) on human colon carcinoma cell lines.
  • To determine the impact of 2-ME on cell cycle progression in colon cancer cells.
  • To explore the potential of 2-ME in inducing apoptosis and autophagy in colon carcinoma.

Main Methods:

  • Treatment of HCT116 and SW613-B3 human colon carcinoma cell lines with 2-methoxyestradiol (2-ME).
  • Assessment of cell proliferation using standard assays.
  • Analysis of cell cycle distribution.
  • Evaluation of apoptosis and autophagy induction.

Main Results:

  • 2-methoxyestradiol (2-ME) demonstrated a significant anti-proliferative effect on both HCT116 and SW613-B3 colon cancer cell lines.
  • 2-ME treatment resulted in cell cycle arrest in the studied colon carcinoma cells.
  • The compound was found to induce both apoptosis and autophagy, key mechanisms in cancer cell death.

Conclusions:

  • 2-methoxyestradiol (2-ME) exhibits potent anti-cancer activity against colon carcinoma cell lines.
  • 2-ME's ability to induce cell cycle arrest, apoptosis, and autophagy suggests its potential as a therapeutic agent.
  • Further investigation into 2-ME as a treatment for colon carcinoma is warranted.

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...